Podcast

Treating Early-Stage HER2-Positive Breast Cancer

Author(s):

OncLive Staff

Dr Gradishar and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Related Videos
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Samilia Obeng-Gyasi, MD, MPH,
Nan Chen, MD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Erin Frances Cobain, MD
Erin Frances Cobain, MD
Related Content
OncLive On Air
May 30th 2024

Revisit Every OncLive On Air Episode From May 2024

Benjamin Levy, MD, clinical director, medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital; associate professor, oncology, Johns Hopkins University School of Medicine
May 30th 2024

Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC

breast
May 28th 2024

Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in High-Risk Early TNBC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Breast Cancer
May 23rd 2024

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

State of the Science Summit - Breast Cancer: Chaired by Suzanne B. Coopey, MD, FACS, and Christie J Hilton, DO
May 23rd 2024

State of the Science Summit - Breast Cancer: Chaired by Suzanne B. Coopey, MD, FACS, and Christie J Hilton, DO